Horizon Therapeutics Pub L - HZNP STOCK NEWS

Horizon Therapeutics plc (Nasdaq: HZNP) announced that CEO Tim Walbert received the 2020 RARE Champion of Hope Industry Partner award from Global Genes for his dedication to the rare disease community. Walbert, who has personal ties to rare diseases, emphasized the company's commitment to delivering breakthrough therapies and raising awareness. This award recognizes leaders who inspire change in rare disease. The event highlighted the #RAREis Playlist initiative, promoting stories of patients living with rare diseases.

Horizon Therapeutics plc (Nasdaq: HZNP) will participate in two key virtual conferences on November 17, 2020. The Jefferies Virtual London Healthcare Conference is scheduled for 5:35 p.m. GMT, followed by the Stifel 2020 Virtual Healthcare Conference at 10:40 a.m. ET. Both presentations will be webcast live and accessible via Horizon's website. The company focuses on developing treatments for rare and rheumatic diseases, emphasizing the importance of combining science and compassion to enhance patient lives.

Horizon Therapeutics plc (Nasdaq: HZNP) announced positive results from the RECIPE trial, the first randomized controlled trial assessing KRYSTEXXA (pegloticase) with mycophenolate mofetil in patients with uncontrolled gout. The trial showed that 86.4% of patients receiving the combination achieved target serum uric acid levels compared to 40% with monotherapy. The study indicates potential for improved treatment efficacy through combination therapy, which may lead to a shift in treatment approaches for patients suffering from chronic gout.

Horizon Therapeutics announced strong financial results for Q3 2020, with net sales reaching $636.4 million, a 90% increase year-over-year. The company has raised its full-year net sales guidance to between $2.12 billion and $2.14 billion, primarily driven by the successful launch of TEPEZZA, expected to exceed $800 million in sales. Additionally, the new executive vice president of R&D, Karin Rosén, has been appointed. Notably, KRYSTEXXA showed a positive response rate of 86% in a recent trial, further enhancing the company's growth outlook.

Horizon Therapeutics plc (Nasdaq: HZNP) has appointed Dr. Karin Rosén as executive vice president, research and development, and chief scientific officer. Reporting to CEO Tim Walbert, Dr. Rosén brings nearly 30 years of experience from major companies, including GlaxoSmithKline and Genentech. Her expertise in clinical development is expected to enhance Horizon's position in the rare disease biopharmaceutical sector. The company has made significant strides in building a robust R&D organization and a diverse pipeline, reflecting its commitment to underserved communities.

Horizon Therapeutics (Nasdaq: HZNP) presented new data on TEPEZZA® (teprotumumab) at the American Academy of Ophthalmology Annual Meeting. TEPEZZA is the first and only FDA-approved treatment for Thyroid Eye Disease (TED), a rare autoimmune disorder. Key presentations include a long-term assessment of proptosis from the OPTIC trial, improvement in fellow eyes of TED patients, and early responses to therapy. A virtual product theater featuring Dr. Raymond Douglas will also occur on November 13, 2020. TEPEZZA's infusion reactions and potential side effects like hyperglycemia were emphasized in the safety information.

AGC Biologics and Horizon Therapeutics are expanding their partnership to manufacture TEPEZZA, a Thyroid Eye Disease treatment, at AGC's new Boulder, CO facility. This facility features two 20,000L bioreactors, enhancing AGC's production capacity. Horizon will be the first client to utilize this site, which aims to produce the majority of TEPEZZA supply post-approval. The collaboration, ongoing since 2017, highlights a successful process transfer and operational efficiency between both companies.

Horizon Therapeutics (Nasdaq: HZNP) has initiated the AGILE clinical trial, enrolling its first patient to assess the tolerability of shorter infusion durations for KRYSTEXXA^® (pegloticase injection) in adults with uncontrolled gout. This Phase 4 study aims to determine the safety and efficacy of KRYSTEXXA paired with methotrexate over durations of 60, 45, and 30 minutes, compared to the standard two-hour infusion. The trial will involve 30 to 50 participants and aims to enhance patient care based on feedback from the community.